165 related articles for article (PubMed ID: 38157359)
1. Portosystemic shunting prevents hepatocellular carcinoma in non-alcoholic fatty liver disease mouse models.
Peloso A; Lacotte S; Gex Q; Slits F; Moeckli B; Oldani G; Tihy M; Hautefort A; Kwak B; Rubbia-Brandt L; Toso C
PLoS One; 2023; 18(12):e0296265. PubMed ID: 38157359
[TBL] [Abstract][Full Text] [Related]
2. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid.
Lau HC; Zhang X; Ji F; Lin Y; Liang W; Li Q; Chen D; Fong W; Kang X; Liu W; Chu ES; Ng QW; Yu J
EBioMedicine; 2024 Feb; 100():104952. PubMed ID: 38176203
[TBL] [Abstract][Full Text] [Related]
3. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Song Q; Zhang X; Liu W; Wei H; Liang W; Zhou Y; Ding Y; Ji F; Ho-Kwan Cheung A; Wong N; Yu J
J Hepatol; 2023 Dec; 79(6):1352-1365. PubMed ID: 37459922
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
5. A Mouse Model of Hepatocellular Carcinoma Induced by Streptozotocin and High-Fat Diet.
Motiño O; Li S; Lambertucci F; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Chen H; Maiuri MC; Kroemer G; Martins I
Methods Mol Biol; 2024; 2769():67-75. PubMed ID: 38315389
[TBL] [Abstract][Full Text] [Related]
6. Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.
Haberl EM; Pohl R; Rein-Fischboeck L; Höring M; Krautbauer S; Liebisch G; Buechler C
Lipids Health Dis; 2020 Dec; 19(1):250. PubMed ID: 33298075
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine.
Kishida N; Matsuda S; Itano O; Shinoda M; Kitago M; Yagi H; Abe Y; Hibi T; Masugi Y; Aiura K; Sakamoto M; Kitagawa Y
BMC Gastroenterol; 2016 Jun; 16(1):61. PubMed ID: 27296438
[TBL] [Abstract][Full Text] [Related]
10. Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet.
Chun HJ; Shim YJ; Kwon YH
J Nutr Biochem; 2022 Feb; 100():108869. PubMed ID: 34563665
[TBL] [Abstract][Full Text] [Related]
11. Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.
Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Sharma A; Ranvir R; Kadam S; Ingale K; Patel H; Nyska A; Jain MR
BMC Cancer; 2023 Jan; 23(1):59. PubMed ID: 36650455
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.
Casagrande V; Mauriello A; Bischetti S; Mavilio M; Federici M; Menghini R
Sci Rep; 2017 Jul; 7(1):6747. PubMed ID: 28751722
[TBL] [Abstract][Full Text] [Related]
13. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease.
Komatsu G; Nonomura T; Sasaki M; Ishida Y; Arai S; Miyazaki T
Exp Anim; 2019 May; 68(2):147-158. PubMed ID: 30487357
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
15. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
19. Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis.
Mohammed S; Thadathil N; Ohene-Marfo P; Tran AL; Van Der Veldt M; Georgescu C; Oh S; Nicklas EH; Wang D; Haritha NH; Luo W; Janknecht R; Miller BF; Wren JD; Freeman WM; Deepa SS
Mol Cancer Res; 2023 Sep; 21(9):933-946. PubMed ID: 37204757
[TBL] [Abstract][Full Text] [Related]
20. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
